0RKL Stock Chart & Stats
kr259.40
kr4.20(1.67%)
At close: 4:00 PM EDT
kr259.40
kr4.20(1.67%)
Day’s Range― - ―
52-Week Rangekr160.80 - kr314.00
Previous CloseN/A
Volume1.88K
Average Volume (3M)4.42K
Market Cap
kr7.45B
Enterprise Valuekr8.00K
Total Cash (Recent Filing)kr304.96M
Total Debt (Recent Filing)kr121.62M
Price to Earnings (P/E)84.7
Beta1.31
Next Earnings
Oct 22, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)2.81
Shares Outstanding31,499,470
10 Day Avg. Volume5,759
30 Day Avg. Volume4,415
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)2.78
Price to Sales (P/S)7.24
P/FCF Ratio-38.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.51
Revenue Forecast (FY)kr990.90M
Bulls Say, Bears Say
Bulls Say
Strong Organic GrowthThe broad acceleration in organic sales indicates growing adoption of XVIVO’s transplantation products and workflows. Sustained expansion across multiple periods can support operating leverage, strengthen customer relationships, and provide a durable foundation for continued investment in commercial scale.
Thoracic And EVLP MomentumThoracic growth combines strong procedure-linked disposable momentum with an attractive gross margin profile. Increasing use of EVLP can deepen integration into transplant workflows, support recurring consumable revenue, and improve the economics of the company’s established market position.
Very Conservative Balance SheetMinimal leverage gives XVIVO considerable resilience and flexibility as it funds regulatory work, sales expansion, and production scale-up. A strong equity base reduces refinancing exposure and allows the company to pursue strategic growth investments without relying heavily on additional debt.
Bears Say
Services Segment WeaknessWeak service revenue and low utilization are weighing on profitability in a business area intended to deepen customer integration. Unless organ recovery volumes improve, underused capacity and operating costs could continue diluting group margins and limit the benefits of recurring service revenue.
Abdominal Margin PressureAbdominal growth is not translating proportionally into earnings because product mix and pricing are reducing margins. This creates a durable execution challenge: XVIVO must improve geography mix, lower component costs, and optimize processes before the segment can deliver stronger profit contribution.
Regulatory Timing UncertaintyUncertain regulatory timing can delay commercialization, revenue realization, and the recovery of development investments in heart products. Delays would also extend the period before new indications contribute mature margins, making near-term execution dependent on external review milestones.
Xvivo Perfusion AB News
0RKL FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest share price was kr160.80 and its highest was kr314.00 in the past 12 months.
What is Xvivo Perfusion AB’s market cap?
Xvivo Perfusion AB’s market cap is kr7.45B.
When is Xvivo Perfusion AB’s upcoming earnings report date?
Xvivo Perfusion AB’s upcoming earnings report date is Oct 22, 2026 which is in 22 days.
How were Xvivo Perfusion AB’s earnings last quarter?
Xvivo Perfusion AB released its earnings results on Jul 14, 2026. The company reported kr0.65 earnings per share for the quarter, missing the consensus estimate of kr0.754 by -kr0.104.
Is Xvivo Perfusion AB overvalued?
According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued.
Does Xvivo Perfusion AB pay dividends?
Xvivo Perfusion AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of 0.12%. See more information on Xvivo Perfusion AB dividends here
What is Xvivo Perfusion AB’s EPS estimate?
Xvivo Perfusion AB’s EPS estimate is 0.76.
How many shares outstanding does Xvivo Perfusion AB have?
Xvivo Perfusion AB has 31,499,470 shares outstanding.
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Xvivo Perfusion AB reported an EPS of kr0.65 in its last earnings report, missing expectations of kr0.754. Following the earnings report the stock price went down -7.901%.
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
Currently, no hedge funds are holding shares in GB:0RKL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.
0RKL Company Deck
0RKL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial picture: strong organic revenue growth (36% in Q2), robust profitability (19% Q2 EBITDA margin; rolling 12-month EBITDA 21%) and improving cash generation (positive operating cash flow and SEK 305m cash balance). Commercial momentum is broad-based (notably thoracic/EVLP, kidney, and heart pre-launch adoption) and supported by strong clinical evidence (heart trial outcomes and >600 heart transplants). Key risks include services underperformance, margin pressure in abdominal products driven by mix and pricing, elevated R&D/CapEx and regulatory timing uncertainty (CE mark and U.S. pathways). Overall the positive growth, profitability and clinical/regulatory progress outweigh the identifiable execution and timing risks.View all GB:0RKL earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Getinge
―
Vitrolife AB
―
BICO Group AB Class B
―
SciBase Holding AB
―
Sedana Medical AB
―







